Literature DB >> 20053758

Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction.

David C Taussig1, Jacques Vargaftig, Farideh Miraki-Moud, Emmanuel Griessinger, Kirsty Sharrock, Tina Luke, Debra Lillington, Heather Oakervee, Jamie Cavenagh, Samir G Agrawal, T Andrew Lister, John G Gribben, Dominique Bonnet.   

Abstract

Leukemia-initiating cells (LICs) in acute myeloid leukemia (AML) are believed to be restricted to the CD34(+) fraction. However, one of the most frequently mutated genes in AML is nucleophosmin (NPM), and this is associated with low CD34 expression. We, therefore, investigated whether NPM-mutated AMLs have LICs restricted to the CD34(+) fraction. We transplanted sorted fractions of primary NPM-mutated AML into immunodeficient mice to establish which fractions initiate leukemia. Approximately one-half of cases had LICs exclusively within the CD34(-) fraction, whereas the CD34(+) fraction contained normal multilineage hematopoietic repopulating cells. Most of the remaining cases had LICs in both CD34(+) and CD34(-) fractions. When samples were sorted based on CD34 and CD38 expression, multiple fractions initiated leukemia in primary and secondary recipients. The data indicate that the phenotype of LICs is more heterogeneous than previously realized and can vary even within a single sample. This feature of LICs may make them particularly difficult to eradicate using therapies targeted against surface antigens.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20053758      PMCID: PMC2837317          DOI: 10.1182/blood-2009-02-206565

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

Review 1.  Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Vienna experience.

Authors:  E Schraml; H Daxberger; F Watzinger; T Lion
Journal:  Leukemia       Date:  2003-01       Impact factor: 11.528

2.  ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays.

Authors:  Yifang Hu; Gordon K Smyth
Journal:  J Immunol Methods       Date:  2009-06-28       Impact factor: 2.303

3.  Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party.

Authors:  Priya Virappane; Rosemary Gale; Robert Hills; Ioannis Kakkas; Karin Summers; Jane Stevens; Christopher Allen; Claire Green; Hilmar Quentmeier; Hans Drexler; Alan Burnett; David Linch; Dominique Bonnet; T Andrew Lister; Jude Fitzgibbon
Journal:  J Clin Oncol       Date:  2008-06-30       Impact factor: 44.544

4.  CD34 expression on long-term repopulating hematopoietic stem cells changes during developmental stages.

Authors:  S Matsuoka; Y Ebihara; M Xu; T Ishii; D Sugiyama; H Yoshino; T Ueda; A Manabe; R Tanaka; Y Ikeda; T Nakahata; K Tsuji
Journal:  Blood       Date:  2001-01-15       Impact factor: 22.113

5.  Reciprocal expression of CD38 and CD34 by adult murine hematopoietic stem cells.

Authors:  F Tajima; T Deguchi; J H Laver; H Zeng; M Ogawa
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

6.  Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34(+)CD38(-) progenitor cells from patients with acute myeloid leukemia.

Authors:  M Feuring-Buske; D E Hogge
Journal:  Blood       Date:  2001-06-15       Impact factor: 22.113

7.  NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS).

Authors:  Friederike Schneider; Eva Hoster; Michael Unterhalt; Stephanie Schneider; Annika Dufour; Tobias Benthaus; Gudrun Mellert; Evelin Zellmeier; Stefan K Bohlander; Michaela Feuring-Buske; Christian Buske; Jan Braess; Susanne Fritsch; Achim Heinecke; Maria C Sauerland; Wolfgang E Berdel; Thomas Buechner; Bernhard J Woermann; Wolfgang Hiddemann; Karsten Spiekermann
Journal:  Blood       Date:  2009-03-11       Impact factor: 22.113

8.  Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells.

Authors:  David C Taussig; Farideh Miraki-Moud; Fernando Anjos-Afonso; Daniel J Pearce; Kirsty Allen; Christopher Ridler; Debra Lillington; Heather Oakervee; Jamie Cavenagh; Samir G Agrawal; T Andrew Lister; John G Gribben; Dominique Bonnet
Journal:  Blood       Date:  2008-06-03       Impact factor: 22.113

9.  Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice.

Authors:  Brunangelo Falini; Maria Paola Martelli; Cristina Mecucci; Arcangelo Liso; Niccolò Bolli; Barbara Bigerna; Alessandra Pucciarini; Stefano Pileri; Giovanna Meloni; Massimo F Martelli; Torsten Haferlach; Susanne Schnittger
Journal:  Haematologica       Date:  2008-03-26       Impact factor: 9.941

10.  Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.

Authors:  Ramiro Garzon; Michela Garofalo; Maria Paola Martelli; Roger Briesewitz; Lisheng Wang; Cecilia Fernandez-Cymering; Stefano Volinia; Chang-Gong Liu; Susanne Schnittger; Torsten Haferlach; Arcangelo Liso; Daniela Diverio; Marco Mancini; Giovanna Meloni; Robin Foa; Massimo F Martelli; Cristina Mecucci; Carlo M Croce; Brunangelo Falini
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-28       Impact factor: 11.205

View more
  140 in total

Review 1.  Prostate cancer stem cell biology.

Authors:  C Yu; Z Yao; Y Jiang; E T Keller
Journal:  Minerva Urol Nefrol       Date:  2012-03       Impact factor: 3.720

Review 2.  Concise review: Cancer stem cells and minimal residual disease.

Authors:  Gabriel Ghiaur; Jonathan Gerber; Richard J Jones
Journal:  Stem Cells       Date:  2012-01       Impact factor: 6.277

3.  Decoupling of tumor-initiating activity from stable immunophenotype in HoxA9-Meis1-driven AML.

Authors:  Kenneth D Gibbs; Astraea Jager; Oliver Crespo; Yury Goltsev; Angelica Trejo; Chase E Richard; Garry P Nolan
Journal:  Cell Stem Cell       Date:  2012-02-03       Impact factor: 24.633

4.  From mass cytometry to cancer prognosis.

Authors:  Deborah R Winter; Guy Ledergor; Ido Amit
Journal:  Nat Biotechnol       Date:  2015-09       Impact factor: 54.908

Review 5.  Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.

Authors:  Roland B Walter; Frederick R Appelbaum; Elihu H Estey; Irwin D Bernstein
Journal:  Blood       Date:  2012-01-27       Impact factor: 22.113

Review 6.  Biology and relevance of human acute myeloid leukemia stem cells.

Authors:  Daniel Thomas; Ravindra Majeti
Journal:  Blood       Date:  2017-02-03       Impact factor: 22.113

7.  The influence of mutational status and biological characteristics of acute myeloid leukemia on xenotransplantation outcomes in NOD SCID gamma mice.

Authors:  Martin Culen; Zdenka Kosarova; Ivana Jeziskova; Adam Folta; Jana Chovancova; Tomas Loja; Nikola Tom; Vojtech Bystry; Veronika Janeckova; Dana Dvorakova; Jiri Mayer; Zdenek Racil
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-02       Impact factor: 4.553

Review 8.  Life history trade-offs in cancer evolution.

Authors:  C Athena Aktipis; Amy M Boddy; Robert A Gatenby; Joel S Brown; Carlo C Maley
Journal:  Nat Rev Cancer       Date:  2013-11-11       Impact factor: 60.716

Review 9.  TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells.

Authors:  Yoshikane Kikushige; Toshihiro Miyamoto
Journal:  Int J Hematol       Date:  2013-09-18       Impact factor: 2.490

Review 10.  Translating leukemia stem cells into the clinical setting: Harmonizing the heterogeneity.

Authors:  Breann Yanagisawa; Gabriel Ghiaur; B Douglas Smith; Richard J Jones
Journal:  Exp Hematol       Date:  2016-09-28       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.